Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) released its quarterly earnings results on Friday. The company reported $0.13 earnings per share for the quarter, Zacks reports. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. The company had revenue of $189.89 million for the quarter.
Bavarian Nordic A/S Stock Performance
BVNRY stock traded up $0.43 during midday trading on Friday, reaching $8.25. The company's stock had a trading volume of 7,272 shares, compared to its average volume of 8,382. The stock has a fifty day simple moving average of $7.65 and a two-hundred day simple moving average of $8.51. Bavarian Nordic A/S has a 1 year low of $6.60 and a 1 year high of $14.60. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 11.96 and a beta of 1.44.
About Bavarian Nordic A/S
(
Get Free Report)
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
Further Reading
Before you consider Bavarian Nordic A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bavarian Nordic A/S wasn't on the list.
While Bavarian Nordic A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
